

PUBLICATIONS (peer reviewed)

1. **Klinger JR**, Moalli R, Warburton RR, Wrenn DS, and Hill NS. C-receptor ligand blocks pulmonary clearance of atrial natriuretic peptide in isolated rat lungs. *Proc Soc Exp Biol Med* 201:154-158, 1992.
2. **Klinger JR**, Bensadoun E, and Corrao WM. Pulmonary complications from alveolar accumulation of carbonaceous material in a cocaine smoker. *Chest* 101:1171-1173, 1992.
3. **Klinger JR**, Petit RD, Curtin LA, Warburton RR, Wrenn DS, Steinhilber ME, Field LJ, and Hill NS. Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress atrial natriuretic peptide. *J Appl Physiol* 75:198-205, 1993.
4. **Klinger JR**, Petit RD, Warburton RR, Wrenn DS, and Hill NS. Neutral endopeptidase inhibition attenuates the development of hypoxic pulmonary hypertension in rats. *J Appl Physiol* 75:1615-1623, 1993.
5. Hill NS, **Klinger JR**, Warburton RR, Pietras L, Wrenn DS. Brain natriuretic peptide: Possible role in the modulation of hypoxic pulmonary hypertension. *Am J Physiol* 266:L308-L315, 1994.
6. **Klinger JR**, Arnal F, Warburton RR, Ou L-C, and Hill NS. Down-regulation of pulmonary atrial natriuretic peptide receptors in rats exposed to chronic hypoxia. *J Appl Physiol* 77:1309-1316, 1994.
7. Brem AS, Bina RV, **Klinger JR**, Pietras L, King T, and Werner JC. Glucocorticoid metabolism in the newborn rat heart. *Proc Soc Exp Biol Med* 209:146-151, 1995.
8. Muramatsu M, Tyler RC, Gutkowska J, **Klinger JR**, Hill NS, Rodman DM, and McMurtry IF. Atrial natriuretic peptide activity accounts for increased cGMP in hypoxia-induced hypertensive rat lungs. *Am J Physiol* 272:L1126-1132, 1997.
9. **Klinger JR**, Wrenn DS, Warburton RR, Petit RD, Pietras L, Ou L-C, and Hill NS. Atrial natriuretic peptide expression in rats with different pulmonary hypertensive responses to hypoxia. *Am J Physiol* 273:H411-417, 1997.
10. Colice GL, Hill NS, Lee Y-J, Du H, **Klinger JR**, Leiter, and Ou L-C. Exaggerated pulmonary hypertensive response to monocrotaline in rats susceptible to chronic mountain sickness. *J Appl Physiol* 83:25-31, 1997.
11. Hill NS, Warburton RR, Pietras L, **Klinger JR**. Nonspecific endothelin receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. *J Appl Physiol* 83:1209-1215, 1997.
12. **Klinger JR**, Warburton RR, Pietras L, and Hill NS. Brain natriuretic peptide attenuates the development of pulmonary hypertension in hypoxia-adapted rats. *J Appl Physiol* 84:1646-1652, 1998.
13. **Klinger JR**, Curtin L, Durkin M, Sanchez M, and Matyas B. Multiple cases of life-threatening adenovirus pneumonia in a mental health care center. *Am J Respir Crit Care Med* 157:645-649, 1998.
14. **Klinger JR**, Siddiq FM, Swift RA, Jackson C, Pietras L, Warburton RR, and Hill NS. Plasma C-type natriuretic peptide levels are increased in rats exposed to chronic hypoxia. *Am J Physiol* 275:L645-L652, 1998.
15. **Klinger JR**, Warburton R, Pietras L, Swift, R, John S, Smithies O, and Hill NS. Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. *Am J Physiol* 276:L868-874, 1999.

PUBLICATIONS (peer reviewed, continued)

16. Salameh G, Karamsetty, MR, Warburton RR, **Klinger, JR**, Ou L-C, Hill NS. Differences in acute hypoxic pulmonary vasoresponsiveness between rat strains: role of endothelium. *J Appl Physiol* 87:356-362, 1999.
17. Mehta, S, Nelson DL, **Klinger JR**, Buczko GB, Levy M. Prediction of post-extubation work of breathing. *Crit Care Med* 28:1341-1346, 2000.
18. Karamsetty MR, Nakashima M, Ou L-C, **Klinger JR**, Hill NS. EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats. *Am J Physiol* 280:L458-L464, 2001.
19. Karamsetty MR, , **Klinger JR**, Hill NS. Phytoestrogens restore nitric oxide mediated relaxation in pulmonary arteries of chronically hypoxic rats in vitro. *J Pharmacol Exp Ther* 297:968-974, 2001.
20. Preston, IR, **Klinger JR**, Landzberg MJ, Houtchens J, Neslon D, and Hill NS. Vasoresponsiveness of pulmonary hypertension associated with sarcoidosis. *Chest* 120:866-872,2001.
21. Mehta S, Short K, Schwartz, W, Nelson D, Levy M, Hill NS, Simms HH, **Klinger JR**. A controlled trial of inhaled nitric oxide in patients with the acute respiratory distress syndrome *J Appl Research* 1:73-84, 2001.
22. **Klinger, JR**, Pietras L, Warburton R, Hill NS. Reduced oxygen tension increases atrial natriuretic peptide synthesis and release from atrial cardiac myocytes. *Exp Biol Med* 226:847-853, 2001.
23. Karamsetty, M, **Klinger JR**, Ou L-C, Pietras L, Jackson C, Hill NS. The role of endothelin-1 in strain-related susceptibility to develop hypoxic pulmonary hypertension in rats. *Respir Physiol* 128:219-227, 2001.
24. **Klinger JR**, Warburton R, Pietras L, Oliver P, Fox J, Smithies O, and Hill NS. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy *Amer J Physiol* 282:H58-H65, 2002.
25. Preston IR, **Klinger JR**, Mehta S, and Hill NS. Pulmonary edema in scleroderma patients given inhaled nitric oxide. *Chest* 121:656, 2002.
26. Ward NS, Lin DY, Nelson DL, Houtchens J, Schwartz WA, **Klinger JR**, Hill NS, and Levy MM. successful determination of lower inflection point and maximal compliance in a population of patients with acute respiratory distress syndrome. *Crit Care Med.* 30:963-968, 2002.
27. Karamsetty, M, **Klinger JR**, Hill NS. Evidence for the role of p38 MAP kinase in hypoxia-induced pulmonary vasoconstriction. *Am J Physiol* 283:L859-L866, 2002.
28. Preston IR, Hill NS, Gambardella LS, Warburton RR, **Klinger JR**. Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. *Exp Biol Med.* 2;229:920-5, 2004.
29. Preston IR, **Klinger JR**, Houtches J, Nelson D, Farber HW, Hill NS. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. *Respir Med.* 99:1501-10, 2005.
30. **Klinger JR**, Houtchens J, Thaker S, Hill NS, Farber H. Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. *Chest.*128:618S-619S, 2005.

PUBLICATIONS (peer reviewed, continued)

31. **Klinger JR**, Warburton R, Carino GP, Murray J, Murphy C, Napier M, Harrington EO. Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. *Exp Cell Res.* 312:401-10, 2006.
32. Martin KB, **Klinger JR**, Rounds SI. Pulmonary arterial hypertension: new insights and new hope. *Respirology.* 11:6-17, 2006.
33. **Klinger JR**, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. *Chest.* 129:417-25, 2006.
34. Steiner MK, Preston IR, **Klinger JR**, Criner GJ, Waxman AB, Farber HW, Hill NS. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. *Chest.* 2006 Nov;130(5):1471-80.
35. **Klinger JR**, Murray JD, Casserly B, Alvarez DF, King JA, An SS, Choudhary G, Owusu-Sarfo AN, Warburton R, Harrington EO. Rottlerin causes pulmonary edema in vivo: a possible role for PKC{delta}. *J Appl Physiol.* 2007 Dec;103(6):2084-94.
36. Aliotta JM, Keaney PJ, Warburton RR, Del Tatto M, Dooner MS, Passero MA, Quesenberry PJ, **Klinger JR**. Marrow cell infusion attenuates vascular remodeling in a murine model of monocrotaline-induced pulmonary hypertension. (in review)
37. Gaurav Choudhary G Murray J, Harrington EO, Kouttab N, Rounds S, Klinger JR. Atrial natriuretic peptide inhibits proliferation of pulmonary artery smooth muscle cells via a cGMP-dependent protein kinase pathway. (in review)
38. Stone AC, Machan JC, **Klinger, JR**. Echocardiographic Evidence of Pulmonary Hypertension is Associated with Increased One Year Mortality in Patients with Chronic Obstructive Pulmonary. (submitted).
39. Mehta S, Heffer MJ, Maham N, Nelson DL, **Klinger JR**, Levy MM. Impact of endotracheal tube size on pre-extubation respiratory variables. (submitted).
40. Chan CM, Machan J, Kestin A, **Klinger JR**. Risk Stratification for DVT Prophylaxis in the Medical Intensive Care Unit. (in preparation)

INVITED EDITORIALS AND REVIEWS

1. **Klinger JR** and Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease: evaluation and management. *Chest* 99:718-724, 1991.
2. . Mehta S and **Klinger JR**. Spontaneous Hemothorax. *Clin Pulm Med* 2:305-309, 1995.
3. **Klinger JR**. Hemodynamics and PEEP in the critically ill. *Crit Care Clinics* 12(4):841-864, 1996.
4. **Klinger, JR** and Cutaia M. The natriuretic peptides: clinical applications in patients with chronic obstructive pulmonary diseases. *Chest* 110:1136-1138, 1996.
5. Greene, J and **Klinger, JR**. Inhaled nitric oxide in the treatment of the acute respiratory distress syndrome. *Crit Care Clinics* 14(3):387-409, 1998..
6. Karemsetty, M and **Klinger, JR**. NO: more than just a vasodilator in lung transplantation. *Am J Resp Cell Mol Bio* 26:1-5, 2002.
7. **Klinger, JR**. Inhaled Nitric Oxide for the Treatment of ARDS. *Crit Care Clinics* 18:45-68, 2002.
8. Pulmonary Hypertension Experts Analyze the New ACCP Evidence-Based Clinical Practice Guidelines. *Advances in Pulmonary Hypertension* –3:14-15, 2004.
9. Management of Right Ventricular Failure in Patients with Pulmonary Hypertension and Sepsis. *Advances in Pulmonary Hypertension* – 4:31-35, 2005.
10. Aliotta JM, Passero M, Meharg J, **Klinger J**, Dooner MS, Pimentel J, Quesenberry PJ. Stem cells and pulmonary metamorphosis: new concepts in repair and regeneration. *J Cell Physiol.* 204:725-41, 2005.
11. Steiner MK, Preston IR, **Klinger JR**, Hill NS. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. *Curr Opin Pharmacol.* 2005;5:245-50.
12. **Klinger, JR**. The Nitric Oxide/cGMP Signaling Pathway in Pulmonary Hypertension. *Clin Chest Med* 28:143-168, 2007.
13. Klinger JR. Pulmonary arterial hypertension: an overview. *Semin Cardiothorac Vasc Anesth.* 11:96-103, 2007.
14. Hill NS, **Klinger JR**. Pulmonary hypertension in the intensive care unit: Critical role of the right ventricle. *Crit Care Med.* 35:2210-2211, 2007.
15. **Klinger, JR**. Treating pulmonary hypertension patients in the ICU, *ADVANCE for Managers of Respiratory Care*, (in press)
16. **Klinger JR**. COPD – new faces on an old disease. Guest editor, *Managed Care Interface*, (in press).
17. **Klinger JR**. Hemodynamic Alterations in Sepsis. *Clinics in Chest Medicine* (in press).
18. **Klinger JR**. Assessing response to treatment in pulmonary arterial hypertension. *The Journal of Respiratory Diseases* (in press)
19. Casserly, B, **Klinger JR**. Ambrisentan in the treatment of pulmonary arterial hypertension. *Drug Design, Development and Therapy* (in review)

BOOK CHAPTERS

1. Meharg J and **Klinger JR**. Ventilator Management Strategies in ARDS, in Ventilator Management Strategies For Critical Care, Lung Biology In Health And Disease, Marcel Dekker, New York, NY, Vol 158, pages 393-449, 2001.
2. Rounds S and **Klinger JR**. Pulmonary Hypertension: pathophysiology and clinical disorders, Textbook of Pulmonary Diseases, seventh edition, Lippincott, Williams and Wilkins, Philadelphia, PA., Ed by J Crapo, J Glassroth, J Karlinsky, and T King, Jr., pp. 697-729, 2003.
3. Stone A, **Klinger JR**. The right ventricle in pulmonary hypertension. *Contemporary Cardiology Pulmonary Hypertension*, Humana Press, Totowa, New Jersey. Ed by NS Hill and HW Farber, 2008 pg 93-126.
4. **Klinger, JR**. The Role of Natriuretic Peptides in Pulmonary Vascular Homeostasis. Phosphodiesterases and the pulmonary circulation (in review)
5. Casserly B and **Klinger JR**. Pulmonary Arterial Hypertension in Pregnancy. In: Pulmonary Problems in Pregnancy: Clinical and Research Aspects. Edited by Karen Rosene-Montella and Ghaja Bourjeily in the series titled "Respiratory Medicine" edited by Sharon Rounds (in press).

OTHER PUBLICATIONS AND CITATIONS

1. **Klinger JR** and Donat W. Massive hemoptysis in bullous pemphigoid. *Am J Med* 86:636-7, 1989, (Letter).
2. Citation in *ACP Journal Club*, "Pulmonary artery catheterization", January , 1998.
3. Medical Tribune, (The medical news source for *The New York Times* Syndicate), inter-viewed for comments regarding study entitled "Addition of nitric oxide to oxygen improves cardiopulmonary function in patients with severe COPD, *Chest* 114:29-35, 1998.
4. Figure, Adenovirus Diseases, Cecil Textbook of Medicine 21st edition, pg 1801.